Drug intelligence / Profile preview

ADXS-503 + pembrolizumab

Development stage: Unknown
Lead developer: Advaxis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

ADXS-503 + pembrolizumab is a combination immunotherapy approach for non-small cell lung cancer (NSCLC). ADXS-503 is an off-the-shelf, attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit potent T-cell responses against 22 tumor antigens commonly found in NSCLC (11 hotspot mutations and 11 tumor-associated antigens). Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody approved for the treatment of advanced lung cancer. The combination leverages complementary mechanisms of immune activation and reversal of immune tolerance.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ADXS-503 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADXS-503 + pembrolizumab.

Explore the full profile